Table 1 Disease demographics and management data
Parameter | N (%) |
|---|---|
Age (median) | 62.6 years |
Gender (Female/Male) | 97 (43.0%)/129 (57.0%) |
Histological Grade | |
1–2 | 170 (75.2%) |
3-4 | 46 (20.4%) |
Obstruction Yes/No | 30 (13.2%)/179 (79.2%) |
Perforation Yes/No | 9 (4.0%)/201 (89.0%) |
Primary Site Left/Right | 165 (73.0%)/60 (26.6%) |
Rectum | 71 (31.0%) |
TNM stage at biopsy | |
I-III versus IV | 83 (36.8%)/137 (60.6%) |
Median Follow Up | 73.6 months |
Deaths | 175 (77.4%) |
Line of therapy at Cetuximab administration | |
1st line | 38 (16.8%) |
2nd line | 108 (47.8%) |
3rd line and beyond | 80 (35.4%) |
Type of therapy at Cetuximab administration | |
Irinotecan-based | 153 (48.7%) |
Oxaliplatin-based | 84 (26.7%) |
Both irinotecan and oxaliplatin | 29 (9.2%) |
Only fluoropyrimidine | 6 (1.9%) |
Single-agent Cetuximab | 42 (13.4%) |
Objective Response to Cetuximab | |
All lines of therapy | |
Complete Respone (CR) | 2 (0.9%) |
Partial Response (PR) | 55 (24.4%) |
ORR (CR+PR) | 57 (25.3%) |
Stable disease (SD) | 66 (29.3%) |
Progressive disease (PD) | 70 (31.1%) |
ORR by line of Cetuximab therapy | |
1st line | 17 (44.7%) |
2nd line | 23 (21.5%) |
3rd line | 14 (22.9%) |